Immunic’s (IMUX) Buy Rating Reiterated at HC Wainwright

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $22.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 80.48% from the stock’s previous close.

IMUX has been the topic of a number of other research reports. Wolfe Research assumed coverage on Immunic in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Wedbush started coverage on Immunic in a research report on Monday, August 17th. They set an “outperform” rating and a $45.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Finally, Roth Capital reiterated a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $47.25.

Immunic Trading Down 4.3%

Immunic stock opened at $12.19 on Thursday. Immunic has a 1-year low of $5.06 and a 1-year high of $17.43. The company has a fifty day simple moving average of $14.81 and a 200 day simple moving average of $13.07. The company has a market cap of $166.27 million, a P/E ratio of -2.78 and a beta of 1.41.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.36. On average, equities research analysts forecast that Immunic will post -3.71 EPS for the current year.

Hedge Funds Weigh In On Immunic

Hedge funds and other institutional investors have recently bought and sold shares of the business. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the first quarter valued at approximately $27,000. Qube Research & Technologies Ltd acquired a new position in shares of Immunic during the 3rd quarter worth approximately $29,000. ADAR1 Capital Management LLC acquired a new position in shares of Immunic during the 1st quarter worth approximately $33,000. Two Sigma Investments LP bought a new stake in Immunic in the 3rd quarter valued at $52,000. Finally, Seven Fleet Capital Management LP bought a new stake in Immunic in the 4th quarter valued at $83,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.